0
Neuroprotection is essential in glaucoma treatment.
1
Pressure control is not sufficient for all patients.
2
DLK/LZK pathway is crucial for neuroprotection.
3
AI can enhance trial efficiency and patient selection.
4
Patient compliance remains a significant challenge.
5
Potential benefits for patients with normal-tension glaucoma.
6
Improved diagnostic tools are on the horizon.
7
Research on neuroprotective agents is ongoing and promising.
